ReviewAntimicrobial agents and chemotherapy2012
Resistance to linezolid caused by modifications at its binding site on the ribosome.
Review in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 370 citations in OpenAlex.
- The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics.Antimicrobial agents and chemotherapy · 2014Trial
- Evaluation of Changes inOpen forum infectious diseases · 2026Article
- A genomic framework for tracking antibiotic resistance genes: global dissemination ofAntimicrobial agents and chemotherapy · 2026Article
- Mutations in apicoplast rRNA genes are associated with clindamycin resistance and impair the ability of malaria parasites to infect mosquitoes.Antimicrobial agents and chemotherapy · 2026Article
- Performance of EUCAST disc diffusion and supplementary methods to detect reduced susceptibility to linezolid in enterococci- the NordicAST LRE-study.The Journal of antimicrobial chemotherapy · 2026Article
- Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin: Mechanisms of Action, Drug Interactions, Adverse Effects and Use in Special Situations.Microorganisms · 2026Review
- Molecular basis of linezolid resistance inAntimicrobial agents and chemotherapy · 2026Article
- Meningitis due to pandrug resistant Chryseobacterium gleum: microbiological cure and clinical response with linezolid-based combination therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Antimicrobial Effect of Spices and Their Phytochemicals: A Novel Approach to Overcoming Antibiotic Resistance.MedComm · 2026Review
- Environmental occurrence of optrA-mediated linezolid resistance in Enterococcus isolates and genomic insights into Enterococcus faecium ST54 co-harboring optrA, poxtA, and cfr(D) genes.World journal of microbiology & biotechnology · 2026Article
- Key Proteins and Enzymatic Mechanisms Underlying Drug Resistance in Mycobacterium tuberculosis.Advances in experimental medicine and biology · 2026Review
- A Frameshift Mutation in the MethyltransferaseComputational and structural biotechnology journal · 2026Article
- Optimization of linezolid infusion duration in critically ill patients: a population pharmacokinetic analysis of the trade-off between efficacy and toxicity.Frontiers in pharmacology · 2026Article
- In Silico Lead Identification ofInternational journal of molecular sciences · 2025Article
- Article
- Ongoing independent evolution of linezolid and vancomycin-resistance pELF-type linear plasmids across the One Health spectrum.Antimicrobial agents and chemotherapy · 2025Article
- Linezolid in the Focus of Antimicrobial Resistance ofInternational journal of molecular sciences · 2025Review
- Genomic and clinical characterization of linezolid resistance in Enterococcus species from cancer patients in China.BMC infectious diseases · 2025Article
- Identification of genetic mutations conferring tedizolid resistance in MRSA mutants.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Antibiotic resistance and preventive strategies in foodborne pathogenic bacteria: a comprehensive review.Food science and biotechnology · 2025Review
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linezolid is an oxazolidinone antibiotic in clinical use for the treatment of serious infections of resistant Gram-positive bacteria. It inhibits protein synthesis by binding to the peptidyl transferase center on the ribosome. Almost all known resistance mechanisms involve small alterations to the linezolid binding site, so this review will therefore focus on the various changes that can adversely affect drug binding and confer resistance. High-resolution structures of linezolid bound to the 50S ribosomal subunit show that it binds in a deep cleft that is surrounded by 23S rRNA nucleotides. Mutation of 23S rRNA has for some time been established as a linezolid resistance mechanism. Although ribosomal proteins L3 and L4 are located further away from the bound drug, mutations in specific regions of these proteins are increasingly being associated with linezolid resistance. However, very little evidence has been presented to confirm this. Furthermore, recent findings on the Cfr methyltransferase underscore the modification of 23S rRNA as a highly effective and transferable form of linezolid resistance. On a positive note, detailed knowledge of the linezolid binding site has facilitated the design of a new generation of oxazolidinones that show improved properties against the known resistance mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.